Cardio, Cardio + Resistance Training Improve CVD Risk Profile at One Year
31 Jan 2024
AHA
WEDNESDAY, Jan. 31, 2024 -- In adults with overweight or obesity, aerobic exercise alone or a combined resistance plus aerobic exercise program leads to improvements in composite cardiovascular disease (CVD) risk profiles at one year, according to a study published online Jan. 17 in the European Heart Journal.
Duck-chul Lee, Ph.D., from Iowa State University in Ames, and colleagues randomly assigned 406 adults (aged 35 to 70 years) with overweight or obesity and elevated blood pressure to resistance exercise (102 participants), aerobic exercise (101 participants), combined resistance plus aerobic exercise (101 participants), or a no-exercise control (102 participants). Interventions lasted one hour, three times per week, for one year.
The researchers found that at one year, there were declines in the composite Z-score, indicating improved CVD risk profile, in the aerobic (mean difference, −0.15) and combination (mean difference, −0.16) groups. However, no improvement was seen in the resistance group (mean difference, −0.02). Compared with the resistance group, both aerobic and combination groups had greater reductions in the composite Z-score, with no difference between the aerobic and combination groups. All three exercise groups experienced a decrease in percent body fat at one year. Compared with the control group, the no-exercise group experienced decreases in systolic blood pressure, low-density lipoprotein cholesterol, and fasting glucose.
"If you’re bored with aerobic exercise and want variety or you have joint pain that makes running long distances difficult, our study shows you can replace half of your aerobic workout with strength training to get the same cardiovascular benefits," Lee said in a statement.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.